SCYNEXIS Inc (NASDAQ:SCYX) announced Tuesday that it has tapped Armando Anido to its board of directors.
“On behalf of my fellow board members, I would like to welcome Armando and look forward to his contributions as we carry out the important work of bringing novel antifungal treatments to patients,” said Guy Macdonald, chairman of the board of the New Jersey-based biotech, in a statement.
Anido boasts more than 30 years of experience in the biopharmaceutical sector. Prior to his tenure at Zynerba, Anido served as CEO of NuPathe Inc, which was acquired by Teva Pharmaceuticals in February of 2014. He also previously was at the helm as CEO at Auxilium Pharmaceuticals, which was acquired by Endo Pharmaceuticals in January of 2015.
SCYNEXIS’s lead drug candidate is ibrexafungerp (formerly known as SCY-078), an antifungal agent in clinical development for the treatment of serious and life-threatening fungal infections caused by candida and aspergillus species.
SCYNEXIS shares popped by 3.7% to $0.77 in Tuesday’s morning trading session.
Contact Ellen Kelleher at [email protected]